127243-85-0
基本信息
N-[2-[P-溴苯丙烯盐基氨基]乙基]-5-异喹啉磺酰胺
H-89 DIHYDROCHLORIDE
H-89 HYDROCHLORIDE
N-[2-(P-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE SULFONAMIDE
N-[2-(P-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINESULFONAMIDE 2HCL
N-[2-(P-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE SULFONAMIDE, DIHYDROCHLORIDE
N-(2-[P-BROMOCINNAMYLAMINO]ETHYL)-5-ISOQUINOLINESULFONAMIDE HYDROCHLORIDE
N-[2-[P-BROMOCINNAMYLAMINO]-ETHYL]-5-ISOQUINOLINESULFONMIDE
物理化学性质
| 熔点 | 195-200°C |
| 沸点 | 639.7±65.0 °C(Predicted) |
| 密度 | 1.436 |
| 储存条件 | 2-8°C |
| 溶解度 | H2O: ≥10 mg/mL |
| 酸度系数(pKa) | 10.43±0.50(Predicted) |
| 形态 | powder |
| 形态 | 粉末 |
| 颜色 | off-white |
| 颜色 | 米白色 |
| 稳定性 | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20°C for up to 3 months. |
| 化妆品成分功效 | SKIN CONDITIONING - MISCELLANEOUS BLEACHING |
| CAS 数据库 | 127243-85-0(CAS DataBase Reference) |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H335-H315-H302-H312-H319-H332 |
| 防范说明 | P264-P270-P301+P312-P330-P501-P280-P302+P352-P312-P322-P363-P501-P264-P280-P305+P351+P338-P337+P313P-P261-P271-P304+P340-P312-P264-P280-P302+P352-P321-P332+P313-P362 |
| 安全说明 | S22-S24/25 |
| WGK Germany | 3 |
| 海关编码 | 29350090 |
知名试剂公司产品信息
N-[2-[P-溴苯丙烯盐基氨基]乙基]-5-异喹啉磺酰胺价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/06/05 | HY-15979 | N-[2-[P-溴苯丙烯盐基氨基]乙基]-5-异喹啉磺酰胺 H-89 | 127243-85-0 | 5 mg | 385元 |
| 2026/06/05 | HY-15979 | N-[2-[P-溴苯丙烯盐基氨基]乙基]-5-异喹啉磺酰胺 H-89 | 127243-85-0 | 10 mM * 1 mLin DMSO | 423元 |
| 2026/06/05 | HY-15979 | N-[2-[P-溴苯丙烯盐基氨基]乙基]-5-异喹啉磺酰胺 H-89 | 127243-85-0 | 10 mg | 616元 |
常见问题列表
IC50: 48 nM (protein kinase A)
H-89 inhibits protein kinase A, in competitive fashion against ATP. H-89 causes a dose-dependent inhibition of the forskolin-induced protein phosphorylation, with no decrease in intracellular cyclic AMP levels in PC12D cells. H-89 significantly inhibits the forskolin-induced neurite outgrowth from PC12D cells. H-89 (30 μM) inhibits significantly cAMP-dependent histone IIb phosphorylation activity in PC12D cell lysates. H-89 (1-2 μM) significantly slows the repriming rate in rat skinned fibres, most likely due to it deleteriously affecting the T-system potential. H-89 (10-100 μM) inhibits net Ca 2+ uptake by the SR and affectes the Ca 32 -sensitivity of the contractile apparatus in rat skinned fibres.
H-89 (0.2 mg/100g, i.p.) significantly increases seizure latency and threshold in PTZ-treated animals. H-89 (0.05, 0.2 mg/100 g, i.p.) prevents the epileptogenic activity of bucladesine (300 nM) with significant increase of seizure latency and seizure threshold.